Stock MAP PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News MAP Pharmaceuticals Inc.

Equities

US56509R1086

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for MAP Pharmaceuticals Inc.

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MAP Pharmaceuticals Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of MAP Pharmaceuticals, Inc.
BU
MAP Pharmaceuticals Inc. : Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
PR
MAP Pharmaceuticals Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of MAP Pharmaceuticals, Inc.
PR
MAP Pharmaceuticals Inc. : INVESTOR ALERT: Brannon Law Firm, L.L.C. is Investigating the Proposed Tender Offer/Merger of MAP Pharmaceuticals, Inc. by Allergan, Inc.
BU
MAP Pharmaceuticals Inc. : Law Firm Brower Piven Announces Investigation of MAP Pharmaceuticals, Inc.
BU
MAP Pharmaceuticals Inc. : Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.
PU
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals to Present at Upcoming Investor Conferences
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals to Present at Upcoming Investor Conferences
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX® (dihydroergotamine) New Drug Application
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
PR
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals to Present at Upcoming Investor Conferences
PU
MAP Pharmaceuticals Inc. : MAP Pharmaceuticals Provides Update on LEVADEX® Program
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News MAP Pharmaceuticals Inc.